CN1706867A - 抑制血管新生的融合蛋白质及其用途 - Google Patents
抑制血管新生的融合蛋白质及其用途 Download PDFInfo
- Publication number
- CN1706867A CN1706867A CN 200510073595 CN200510073595A CN1706867A CN 1706867 A CN1706867 A CN 1706867A CN 200510073595 CN200510073595 CN 200510073595 CN 200510073595 A CN200510073595 A CN 200510073595A CN 1706867 A CN1706867 A CN 1706867A
- Authority
- CN
- China
- Prior art keywords
- immunoglobulin
- zone
- flt
- kdr
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 22
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 11
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 10
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims abstract description 54
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims abstract description 51
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims abstract description 50
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 18
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 68
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 68
- 230000004927 fusion Effects 0.000 claims description 63
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 43
- 239000013612 plasmid Substances 0.000 claims description 26
- 108020004414 DNA Proteins 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 5
- 230000031018 biological processes and functions Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 9
- 235000018102 proteins Nutrition 0.000 description 51
- 206010028980 Neoplasm Diseases 0.000 description 29
- 238000000034 method Methods 0.000 description 24
- 238000012360 testing method Methods 0.000 description 15
- 230000000903 blocking effect Effects 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000003556 vascular endothelial cell Anatomy 0.000 description 13
- 230000012010 growth Effects 0.000 description 12
- 238000001890 transfection Methods 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000000370 acceptor Substances 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 102220023256 rs387907547 Human genes 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000012930 cell culture fluid Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 210000003725 endotheliocyte Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 102220369447 c.1352G>A Human genes 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 102220023257 rs387907546 Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 238000002689 xenotransplantation Methods 0.000 description 3
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039361 Sacroiliitis Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 102220369446 c.1274G>A Human genes 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000652 hormesis Toxicity 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 101710153593 Albumin A Proteins 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 101150088608 Kdr gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100735954A CN1304427C (zh) | 2004-06-08 | 2005-06-06 | 抑制血管新生的融合蛋白质及其用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410044965.7 | 2004-06-08 | ||
CN200410044965 | 2004-06-08 | ||
CNB2005100735954A CN1304427C (zh) | 2004-06-08 | 2005-06-06 | 抑制血管新生的融合蛋白质及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1706867A true CN1706867A (zh) | 2005-12-14 |
CN1304427C CN1304427C (zh) | 2007-03-14 |
Family
ID=35580993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100735954A Active CN1304427C (zh) | 2004-06-08 | 2005-06-06 | 抑制血管新生的融合蛋白质及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1304427C (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007112675A1 (fr) * | 2006-03-31 | 2007-10-11 | Chengdu Kanghong Biotechnologies Co., Ltd. | Protéine de fusion du récepteur du vegf et son utilisation |
CN101721699A (zh) * | 2008-10-13 | 2010-06-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用 |
CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
CN101279092B (zh) * | 2007-04-02 | 2010-10-27 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用 |
CN102311502A (zh) * | 2010-07-10 | 2012-01-11 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
CN102380096A (zh) * | 2010-08-31 | 2012-03-21 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
CN102712934A (zh) * | 2009-12-31 | 2012-10-03 | 汉阳大学校产学协力团 | 具有抗血管新生活性的重组腺病毒 |
CN104419714A (zh) * | 2013-08-26 | 2015-03-18 | 深圳先进技术研究院 | 抑制肿瘤血管新生的融合蛋白的基因及其构建方法和应用 |
CN109320614A (zh) * | 2018-02-02 | 2019-02-12 | 温州医科大学 | FGFR-Fc融合蛋白及siRNA |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3195874A1 (en) | 2005-03-25 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
EP2364691B1 (en) | 2006-06-16 | 2013-04-24 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
WO2012097019A1 (en) | 2011-01-13 | 2012-07-19 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6020473A (en) * | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
EP1185559A2 (en) * | 1999-04-28 | 2002-03-13 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
-
2005
- 2005-06-06 CN CNB2005100735954A patent/CN1304427C/zh active Active
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009531036A (ja) * | 2006-03-31 | 2009-09-03 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | Vegf受容体融合タンパク質およびそれらの使用 |
WO2007112675A1 (fr) * | 2006-03-31 | 2007-10-11 | Chengdu Kanghong Biotechnologies Co., Ltd. | Protéine de fusion du récepteur du vegf et son utilisation |
CN101279092B (zh) * | 2007-04-02 | 2010-10-27 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用 |
CN101721699A (zh) * | 2008-10-13 | 2010-06-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用 |
CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
WO2010105573A1 (zh) * | 2009-03-18 | 2010-09-23 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
CN102712934A (zh) * | 2009-12-31 | 2012-10-03 | 汉阳大学校产学协力团 | 具有抗血管新生活性的重组腺病毒 |
CN102311502A (zh) * | 2010-07-10 | 2012-01-11 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
CN102380096A (zh) * | 2010-08-31 | 2012-03-21 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
CN102380096B (zh) * | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
CN104419714A (zh) * | 2013-08-26 | 2015-03-18 | 深圳先进技术研究院 | 抑制肿瘤血管新生的融合蛋白的基因及其构建方法和应用 |
CN109320614A (zh) * | 2018-02-02 | 2019-02-12 | 温州医科大学 | FGFR-Fc融合蛋白及siRNA |
CN109320614B (zh) * | 2018-02-02 | 2023-03-24 | 温州医科大学 | FGFR-Fc融合蛋白及siRNA |
Also Published As
Publication number | Publication date |
---|---|
CN1304427C (zh) | 2007-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1304427C (zh) | 抑制血管新生的融合蛋白质及其用途 | |
CN1263507C (zh) | April受体(bcma)及其用途 | |
CN1235911C (zh) | 多细胞因子-抗体复合物 | |
KR100897379B1 (ko) | 혈관신생-저해 키메릭 단백질 및 그 사용 | |
CN1308037C (zh) | 增强蛋白和肽抗原免疫原性的Fc融合蛋白 | |
CN1483041A (zh) | Glp-1融合蛋白 | |
CN1958615A (zh) | 功能人源化抗人cd20抗体及其应用 | |
KR100888022B1 (ko) | 면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc | |
CN1869207A (zh) | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 | |
CN1124348C (zh) | 多功能性造血受体激动剂 | |
CN1234731C (zh) | 具有高度生物活性的人促红细胞生成素的Fc融合蛋白 | |
CN1298412A (zh) | G-csf受体兴奋剂抗体及其筛选方法 | |
CN1305527A (zh) | 血管发生相关分子 | |
CN1212334C (zh) | 人唾液酸结合性免疫球蛋白样凝集素,其编码序列及用途 | |
CN114507291A (zh) | 一种重组人免疫球蛋白ε和γ的Fc融合蛋白的表达方法 | |
KR101572912B1 (ko) | 돼지 cd7 유전자 및 이를 이용한 cd7 융합 이뮤노글로불린 | |
CN1263771C (zh) | 骨保护素融合蛋白的制备方法和用途 | |
CN1179976C (zh) | 产生凝血因子ⅷ的生产方法和宿主细胞 | |
CN87102725A (zh) | 重组产品 | |
CN1244375C (zh) | 人肝再生相关蛋白及其应用 | |
CN1580265A (zh) | T-20融合蛋白、其制备方法及用途 | |
CN1300170C (zh) | 新型DnaJ/Hsp40分子DC-DJIII,其编码序列及用途 | |
CN1520884A (zh) | 免疫调节剂及其应用 | |
CN1273485C (zh) | 新型人树突状细胞来源的免疫球蛋白样受体,其编码序列及用途 | |
CN101371923B (zh) | Baff受体(bcma),一种免疫调节剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: KANGHONG BIOTECH CO., LTD., CHENGDU Free format text: FORMER OWNER: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO., LTD. Effective date: 20060414 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060414 Address after: 610036 No. 36 Shu West Road, Chengdu, Jinniu District Applicant after: CHENGDU KANGHONG BIOTECHNOLOGIES Co.,Ltd. Address before: 610036 No. 36 Shu West Road, Sichuan, Chengdu Applicant before: Chengdu Kanghong technology industry (Group) Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C35 | Partial or whole invalidation of patent or utility model | ||
IP01 | Partial invalidation of patent right |
Commission number: 4W02804 Conclusion of examination: On the basis of the revised text (1 pages, 7 claims) submitted by the patent holder in January 8, 2010, the patent right for invention No. 200510073595.4 is valid. Decision date of declaring invalidation: 20100518 Decision number of declaring invalidation: 14826 Denomination of invention: Angiogenesis inhibiting fusion protein and its use Granted publication date: 20070314 Patentee: CHENGDU KANGHONG BIOTECHNOLOGIES Co.,Ltd. |